RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET ANALYSIS

Respiratory Syncytial Virus Diagnostics Market, by Diagnostic Technique (Molecular Diagnostics, Direct Fluorescent Antibody Method, Rapid Antigen Diagnostic Test, Monoclonal Antibodies, Flow Cytometry, Diagnostic Imaging, Immnunochromgraphic Assay, Gel Microdroplets, and Others), by End User (Hospitals, Diagnostic Centers, and Others), and by Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Key Development

In May 2019, QIAGEN N.V. received 510 (k) clearance from US Food and Drug administration (FDA) for its QIAstat-Dx syndromic testing system
In 2016, BD (Becton, Dickinson and Company) launched its next generation wireless rapid diagnostic system Veritor Plus.
In 2017, Abbott Laboratories completed acquisition of the Alere, Inc. which provides RSV diagnostic system such as ALERE i RSV.
In 2016, Abbott Laboratories received the US Food and Drug Administration (FDA) approval and CLIA waivers for its Alere i RSV Rapid Molecular Test and Alere Reader Lateral Flow Assay Analyzer respectively.
In September 2015, Roche Diagnostics received CLIA from the US Food and Drug Administration (FDA) for detection of flu A/B, RSV, and Strep A using the cobas Liat System. Post the approval the system may be used in pharmacy clinics, hospitals, physician offices, and other healthcare providing facilities.
In 2014, bioMérieux acquired BioFire Diagnostics Inc., which is a privately held U.S.-based company specialized in manufacturing molecular biology.